Eurofins Discovery Services North America LLC.

Eurofins Discovery Services North America LLC. is a global contract research organization (CRO) supporting drug discovery programs from early discovery through the preclinical stage. The company provides in-house safety, efficacy, and pharmacokinetic studies, offering an integrated, end-to-end solution spanning target identification through lead and candidate selection.
With proprietary laboratories and dedicated scientific teams, Eurofins Discovery Services North America LLC. delivers directly managed, high-quality nonclinical research services.

Features of Eurofins Discovery Services North America LLC.’s Contract Services for Non-Clinical Studies

Comprehensive off-target safety profiling

Eurofins Discovery Services North America LLC. offers extensive safety profiling through thousands of assays, including SafetyScreen™ and SAFETYscan®, enabling comprehensive evaluation of off-target activities of candidate compounds.
By integrating binding and functional analyses, potential safety liabilities can be identified early, reducing attrition risk during development.
In addition, data visualization via In Vitro Safety Insight allows intuitive assessment of organ-specific adverse responses.

High-precision ADME and pharmacokinetic evaluation

With access to more than 500 in vitro ADME and toxicity assays, Eurofins Discovery Services North America LLC. conducts detailed analyses of absorption, distribution, metabolism, and excretion properties.
Safety endpoints such as hepatotoxicity, nephrotoxicity, and cardiotoxicity are evaluated in parallel, supporting early-stage risk mitigation.
The resulting datasets contribute to more accurate candidate selection while helping to shorten development timelines and reduce overall costs.

Target characterization and efficacy assessment with LeadHunter™

Through the LeadHunter™ platform, Eurofins Discovery Services North America LLC. provides in vitro pharmacology assays covering key target classes including GPCRs, kinases, and ion channels.
Binding affinity and selectivity are rapidly assessed to support lead optimization.
The combination of high data reproducibility and fast turnaround enables efficient progression toward preclinical candidate selection.

Examples of Disease Models Available at Eurofins Discovery Services North America LLC.

MASH LeadHunter® Panel (PP318)

This panel includes major targets involved in glucose, lipid, and bile acid metabolism—such as THRβ, FXR, and PPAR—and enables comprehensive analysis of mechanisms of action from metabolic regulation to inflammation and fibrosis. It is well suited for MOA elucidation and early-stage screening in MASH drug discovery programs.

TGFβ-induced liver fibrosis cell model

Using the human hepatic stellate cell line LX-2, this model reproduces the fibrotic process induced by TGFβ stimulation. Antifibrotic efficacy can be evaluated using COL1A1 expression as a readout, making it a valuable in vitro model for assessing candidate therapeutics for MASH and liver fibrosis.

Eurofins Discovery Services North America LLC. Non-Clinical Case Study

Validation of functional assays for safety assessment

Using SAFETYscan® functional assays, 26 marketed drugs were evaluated across 17 liability targets and compared with radioligand binding data generated by Novartis.
The results demonstrated strong concordance between activity values obtained from both methods, while functional assays additionally enabled discrimination of mechanisms of action (MoA).
This case study highlights how incorporating functional safety assays at early discovery stages can facilitate early identification of off-target effects and improve candidate selection prior to animal studies.

Eurofins Discovery Services North America LLC. Company Information